Skip to main content
Premium Trial:

Request an Annual Quote

Cancer Genetics Lowers Expected Proceeds from IPO, Increases 2012 Revenues

NEW YORK (GenomeWeb News) – Cancer Genetics again lowered the amount it expects to raise in its pending initial public offering.

In a Form S-1/A filed with the US Securities and Exchange Commission on Monday, the Rutherford, NJ-based firm said that it expects to offer 1.85 million shares of stock in its IPO at a price of between $10 and $12 per share.

At the midpoint price of $11 per share, net proceeds from the offering is estimated at $16.3 million, Cancer Genetics said. If the offering's underwriters, Aegis Capital and Feltl and Co., exercise their over-allotment option, the net proceeds would rise to about $19.2 million, it added.

Cancer Genetics filed for its IPO in late December 2011, hoping to raise $48.6 million, but it has lowered that target several times, most recently to $23.5 million.

The company effected a one-for-two reverse stock split on February 8, and a one-for-2.5 reverse stock split on March 1.

If approved, Cancer Genetics' stock would list on Nasdaq under ticker symbol "CGIX".

Proceeds from the IPO would be used to repay "certain outstanding indebtedness"; fund R&D and regulatory submissions, as well as potential product launches and collaboration; hire additional sales and marketing staff; fund Cancer Genetics' joint venture with the Mayo Foundation for Medical Education and Research to develop oncology diagnostic services and tests using next-generation sequencing; and fund ongoing operations and business expansion, the company said.

The company also disclosed its earnings for 2012 in its SEC document. For full-year 2012 it took in $4.3 million in revenues, up 43 percent from $3.0 million in 2011.

Its R&D expenses were essentially flat at $2.1 million, while its SG&A costs were down 2 percent to $5.9 million from $6.0 million.

Cancer Genetics' net loss for the year was $6.7 million, or $10.55 per share, compared to a net loss of $19.9 million, or $15.61 per share, in 2011.

Last week, the firm announced it received CLIA and New York State approval for the clinical use of its mature B-cell neoplasm array to assist clinicians in the diagnosis and prognosis of diffuse large B-cell lymphoma.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.